A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma

被引：11
|
作者：
Bennouna, J
Delva, R
Gomez, F
Lesimple, T
Geoffrois, L
Linassier, C
Chevreau, C
Douillard, JY
Négrier, S
机构：
[1] Ctr Rene Gauducheau, F-44805 Nantes, France
[2] Ctr Paul Papin, Angers, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Ctr Eugene Marquis, Rennes, France
[5] Ctr Alexis Vautrin, Nancy, France
[6] CHRU Bretonneau, Tours, France
[7] Inst Claudius Regaud, Toulouse, France
来源：
ONCOLOGY | 2003年 / 64卷 / 01期
关键词：
metastatic renal cell carcinoma; 5-FU; oxaliplatin;
D O I：
10.1159/000066518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Purpose: To investigate the efficacy and safety of the FOLFOX-4 regimen for patients with metastatic renal cell carcinoma (MRCC). Patients and Methods: Fifty-nine patients (median age 59 years) pre-treated or not by cytokines (29 vs. 30) received the FOLFOX-4 regimen every 2 weeks. Results: Three minor responses, and no complete or partial responses were obtained. The median progression-free survival was 3 months (95% Cl: 2.6-3.4), the median survival 10.6 months (95% Cl: 8.7-12.4), with no difference between pre-treated patients and others. Treatment was well tolerated. Conclusion: The FOLFOX-4 regimen is ineffective in patients with MRCC. We believe that oxaliplatin should no longer be explored in renal carcinoma. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码：25 / 27
页数：3
相关论文
共 50 条
  • [1] Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma - Results of a pilot study
    Chaouche, M
    Pasturaud, AL
    Kamioner, D
    Grandjean, M
    Franiatte, J
    Tourani, JM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (03): : 288 - 289
  • [2] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [3] Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
    Pierpaolo Correale
    Fabio Fulfaro
    Stefania Marsili
    Giuseppe Cicero
    Eugenia Bajardi
    Chiara Intrivici
    Giuseppe Vuolo
    Antonio Ferdinando Carli
    Michele Caraglia
    Salvatore Del Prete
    Ettore Greco
    Nicola Gebbia
    Guido Francini
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 563 - 568
  • [4] Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer
    Correale, P
    Fulfaro, F
    Marsili, S
    Cicero, G
    Bajardi, E
    Intrivici, C
    Vuolo, G
    Carli, AF
    Caraglia, M
    Del Prete, S
    Greco, E
    Gebbia, N
    Francini, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) : 563 - 568
  • [5] A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
    De Vita, F
    Orditura, M
    Matano, E
    Bianco, R
    Carlomagno, C
    Infusino, S
    Damiano, V
    Simeone, E
    Diadema, MR
    Lieto, E
    Castellano, P
    Pepe, S
    De Placido, S
    Galizia, G
    Di Martino, N
    Ciardiello, F
    Catalano, G
    Bianco, AR
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1644 - 1649
  • [6] A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
    F De Vita
    M Orditura
    E Matano
    R Bianco
    C Carlomagno
    S Infusino
    V Damiano
    E Simeone
    M R Diadema
    E Lieto
    P Castellano
    S Pepe
    S De Placido
    G Galizia
    N Di Martino
    F Ciardiello
    G Catalano
    A R Bianco
    British Journal of Cancer, 2005, 92 : 1644 - 1649
  • [7] 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer.
    Figer, A
    Perez, N
    Carola, E
    Andre, T
    Chirivella, I
    Lledo, G
    Flesch, M
    Rivera, F
    Colin, P
    De Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 262S - 262S
  • [8] 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in poor prognosis patients with metastatic colorectal cancer.
    Tournigand, C
    Andre, T
    Chirivella, I
    Figer, A
    Lledo, G
    Flesch, M
    Lorenzo, JRM
    Achille, E
    Landi, B
    Hebbar, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 261S - 261S
  • [9] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
    Rothenberg, M. L.
    Cox, J. V.
    Butts, C.
    Navarro, M.
    Bang, Y. -J.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Laguerre, S.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
  • [10] A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
    Chiesa, Matteo Dalla
    Buti, Sebastiano
    Tomasello, Gianluca
    Negri, Federica
    Buononato, Massimo
    Brunelli, Antonio
    Lazzarelli, Silvia
    Brighentl, Matteo
    Donati, Gianvito
    Passalacqua, Rodolfo
    TUMORI, 2007, 93 (03) : 244 - 247
12345